Asep Inc. Signs Definitive Agreement for Joint Venture with Bahrain-based Seaspring W.L.L. for Regulatory Approval and Commercialization of Sepsis Diagnosis Technology in the Kingdom of Bahrain, the Middle East and North Africa
Pictured left to right, Dr. Robert E. W. Hancock and Shaikh Isa bin Khalid Al-Khalifa sign the joint venture’s definitive agreement.
VANCOUVER, BC, June 9, 2023 /PRNewswire/ – Pursuant to the signing of a Letter of Intent (LOI) in December 2022, Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is delighted to announce it has signed a definitive agreement (“agreement”) for a joint venture with Bahrain-based international investment consultancy firm, Seaspring W.L.L. (“Seaspring”), to advance regulatory approval and commercialization of the Company’s sepsis diagnosis technology (SepsetER TM) in the Kingdom of Bahrain and the Middle East and North Africa (MENA).
Related news for (SEPSF)
- Asep Medical Featured in National Documentary
- Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST
- Asep Medical Confirms the Use of AI – Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics
- Asep Medical’s Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
- ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT